 x 0
 x 0
|
Despite the sell-off in share price this two days, short-sell still stands at 58% today, pretty relentless short-sellers
Newbie2025 ( Date: 14-May-2026 20:11) Posted:
Thank you Sir..
If institutions r selling, wah the retail buyers got so much to buy 300 over mil shares..
Or ciuld it stil be some fund mgrs who buy at low..😂
sgng123 ( Date: 14-May-2026 15:47) Posted:
| It institution players selling cos genS financial fact fall outside their fund requirement |
|
|
|
|
|
Good Post
Bad Post
|
x 0
x 0
|
Stock is at multi-year low back to COVID times and if management has committed to 4c DPS then current price of 6.7% has good downside protection. Paid to wait.
|
|
Good Post
Bad Post
|
x 0
x 0
|
Would have thought that the volume yesterday had a huge amount of short covering but it seems like short interest remains elevated with 48.5% of yesterday volume being short-sell (per SGX short-sell trade data) - guess the downside protection will be the 4c dps to give the yield although mindful to note that its not a dividend policy but a guidance
sgng123 ( Date: 13-May-2026 22:21) Posted:
| Indiscriminal shorting for disappointment. |
|
|
|
Good Post
Bad Post
|
x 0
x 0
|
Dont think this stock has gotten to the radar of the broader investment community yet about its exposure and beneficiary of the semicon upcycle - or at least the insti capital given its relatively smaller size and had only just turned profitable in FY25 after years of losses
stlimst ( Date: 13-May-2026 21:03) Posted:
Looking at the surging semicond stocks (AEM, UMS, Frencken and Micro-Mechanics), ASTI will surpass $0.20 for sure.
Sooner rather than later.
n3wbie ( Date: 13-May-2026 19:58) Posted:
If this stock starts riding on the fund flows rotating into semi-con plays like AEM, UMS - a rerating awaits?
Not sure if they publish 1Q business update but would be keen to see if the turnaround they achieved is sustainable. |
|
|
|
|
|
Good Post
Bad Post
|
x 0
x 0
|
If this stock starts riding on the fund flows rotating into semi-con plays like AEM, UMS - a rerating awaits?
Not sure if they publish 1Q business update but would be keen to see if the turnaround they achieved is sustainable.
|
|
Good Post
Bad Post
|
x 0
x 0
|
GENS resumed their SBB finally. Repurchased 4m shares from 615 - 645. Lets see if they continue to do more to support the share price.
|
|
Good Post
Bad Post
|
x 0
x 0
|
They have been paying 2c DPS per half year so that adds to 4c DPS for the full year
Newbie2025 ( Date: 13-May-2026 12:36) Posted:
Sir, i dont get it. Is it they could be giving one time dividend once a year?
sgng123 ( Date: 13-May-2026 12:27) Posted:
| From DBS research look like genS harden resolve to give guarantee 4 cents DPS
It another way to unlock value through progressive DPS.
Instead 1 lump sum, they spread it out over a few years. |
|
|
|
|
|
Good Post
Bad Post
|
x 0
x 0
|
q/q improvement but y/y decline - would imagine y/y to be more reflective adjusted for seasonality. Assuming they dont cut DPS then the yield is attractive and will serve as downside protection for the stock
belugacat ( Date: 12-May-2026 19:31) Posted:
Never say die! Don' t give up so easily.
Revenue, EBITDA, and Net Profit for the 1st Quarter 2026 is better than the 4th Quarter 2025 results
So, it is still improving step by step, although slightly
It is not the END yet! |
|
|
|
Good Post
Bad Post
|
x 0
x 0
|
The key concern is that the gaming business has declined y/y while MBS is delivering record revenue so it is clearly losing market share for the gaming business while the non-gaming is not growing fast enough to offset the decline.
|
|
Good Post
Bad Post
|
x 0
x 0
|
Rally continues?
|
|
Good Post
Bad Post
|
x 0
x 0
|
Guess having the stock to trade in dual currency, USD and SGD is good but not sure if that materially changes much - seems like the sell-off continues and on the way to setting new lows. Time for management, board and their IR to do something!
|
|
Good Post
Bad Post
|
x 0
x 0
|
Given all the EQDP and value up program here, shouldnt GENS be a beneficiary esp since it only has SG only exposure?
|
|
Good Post
Bad Post
|
x 0
x 0
|
The market cap needs to recover to ~US$1.6b or > S$2b which is the requirement for Nasdaq listing but more importantly, what would be the use of those proceeds? They have been cash flow positive so unless they put their cash raised from SGX IPO to work more and have a need to raise additional equity with the Nasdaq listing for growth capital else it would be dilutive to shareholders.
Would want to see them start giving some dividends or at least support share price with share buyback.
alexvar ( Date: 06-May-2026 11:21) Posted:
pretty amazing!
Next would be cool to see them getting secondary listed on Nasdaq - when and how would it be possible?
since America is their largest market.
Joelton ( Date: 06-May-2026 09:30) Posted:
UltraGreen.ai secures regulatory approval for Verdye in Singapore
UltraGreen.ai (SGX:ULG) announced that it secured regulatory approval for Verdye (indocyanine green for injection) in Singapore.
The company believes this approval is a strategic step in its Southeast Asia growth strategy, which will help in expanding its addressable market and strengthening its presence in a key regional healthcare hub.
&ldquo Singapore plays a critical role as a centre for clinical excellence and regional influence, supporting broader adoption of advanced surgical technologies across Southeast Asia,&rdquo the company adds.
Through the approval, it will enable Utragreen.ai to advance commercialisation efforts, deepen partnerships with leading healthcare institutions, and support clinical adoption of fluorescence-guided surgery.
&ldquo This approval reinforces our strong regulatory execution and clear momentum in our regional strategy. We are well positioned to support surgeons with proven fluorescence-guided solutions while laying the groundwork for continued growth and innovation across Southeast Asia,&rdquo says Ravi Sajwan, CEO of Ultragreen.ai.
|
|
|
|
|
|
Good Post
Bad Post
|
x 0
x 0
|
As long as they maintain dividends at 2c per half year and 4c dps for full year, share price will trough given dividend yield buffer unless there are other fundamental issues impacting its earnings recovery.
|
|
Good Post
Bad Post
|
x 0
x 0
|
Based on last 3-4 years timing, they seem to always publish around 2nd week of May before 15 May.
tongphlp ( Date: 05-May-2026 14:54) Posted:
can' t c or forecast clearly...yet
n3wbie ( Date: 05-May-2026 13:17) Posted:
| Any visibility on when they might do their 1Q update? |
|
|
|
|
|
Good Post
Bad Post
|
x 0
x 0
|
Only makes sense if they buy back at current or lower valuations and then issue new shares on Nasdaq at higher multiples - at least in a textbook and ideal setting, if Mr Market permits. For now, they need to get the right investors and eyeballs on the stock. A rare healthcare and growth stock yet share price continues to underperform.
investshare ( Date: 05-May-2026 16:22) Posted:
| I thought they plan dual listing on nasdaq, buy back share does not seem make sense. |
|
|
|
Good Post
Bad Post
|
x 0
x 0
|
Any visibility on when they might do their 1Q update?
|
|
Good Post
Bad Post
|
x 1
x 0
|
DBS update note
1Q26 Business Update: Sequential growth points to healthy underlying demand
- Soft y/y volume is largely a function of a high comparison base rather than a material slowdown in underlying demand
- Full-year growth outlook remains intact, supported by ASP and volume growth
- Secured regulatory approval for Verdye in Singapore, and is pursuing approvals in 20 additional markets
- Maintain BUY with TP USD2.00
Soft y/y volume is largely a function of a high comparison base, while sequential growth points to healthy underlying demand. 1Q26 volumes stood at 280.9k vials (-8.7% y/y, +7.8% q/q, roughly 25% of our FY26 volume estimates), following an exceptionally strong 1Q25 when backlog fulfilment lifted shipments after earlier supply chain disruptions from June to October 2024 caused by a supply shortage at Ultragreen&rsquo s contract manufacturer. US volumes declined 20.3% y/y given the high base, while non-US volumes rose 25.7% y/y off a small base, as RoW sales were deprioritised last year in favour of higher-ASP shipments to the Americas. On a sequential basis, volumes grew 3.1% in US and 18.1% in non-US markets, indicating that core demand continued to grow from a normalised base in 4Q25. While no revenue figures were provided in this business update, we believe the higher average selling price in 1Q26 relative to 1Q25 likely offset the y/y volume decline, leaving revenue broadly flattish. In our view, Ultragreen is likely tracking its revenue guidance of USD170&ndash 190mn (+26% y/y) given that it typically has limited seasonality. Overall, we view 1Q26 as more reflective of base effects than any material slowdown in underlying demand. Ultragreen also announced regulatory approval for Verdye in Singapore, a key regional reference point for clinical adoption across Southeast Asia. This expands its regulatory coverage to 41 countries. Approvals are being pursued in c.20 additional markets across Asia and the Middle East, which should further strengthen Ultragreen&rsquo s moat and support its regional expansion strategy.
Full-year growth outlook remains intact, supported by ASP and volume growth. We believe Ultragreen is well positioned to meet its revenue target, reflecting the annualisation of higher average selling prices and continued volume growth as ICG adoption expands across procedures. Looking ahead on a quarterly basis, we continue to expect some noise, with 3Q26 likely to show stronger headline y/y growth off a low base, as the softer prior-year quarter reflected a transitional period during the switch from the legacy ICG USP product to IC-GREEN, which took time to fully bed into hospital procurement and distribution systems. In the longer term, Ultragreen remains well positioned to benefit from rising ICG adoption, supported by strong ecosystem growth. Clinical trials have increased 38% since FY23, peer-reviewed publications are up 16% year on year in 2025, and the installed base of robotic systems has tripled between 2015 and 2025. Separately, management highlighted progress in diversifying its lyophilisation network, having expanded from two contractors previously to four currently, with an additional supplier under qualification. This should reduce concentration risk and better support future demand growth. Maintain BUY with TP USD2.00.
|
|
Good Post
Bad Post
|
x 0
x 0
|
Paid to wait, hopefulyl!
alanchee ( Date: 03-May-2026 20:37) Posted:
Right, if 1q results performance is better than expected then sp will go up. else just wait lor, at least the div is much higher than fd and at this price very very cheap imo
n3wbie ( Date: 03-May-2026 00:07) Posted:
| Every dog has its day - take comfort that it pays decent dividends at 5-6% yield despite profit decline and the net cash buffer of $3b+. Hopefully 1Q reports a decent operational update on y/y performance. I would love to see them continue with their share buyback which was undertaken previously when stock was trading below 70c pre ex d |
|
|
|
|
|
Good Post
Bad Post
|
x 0
x 0
|
1Q business update will be announced before market on Tue, 5 May so perhaps that will determine if that can support the breakout?
JurongW ( Date: 01-May-2026 16:50) Posted:
Updated chart as of 30 Apr, 5pm
 |
|
|
|
Good Post
Bad Post
|
About n3wbie
Go to Message